NCT05353439 - Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions

Extensive Stage Lung Small Cell CarcinomaLimited Stage Lung Small Cell CarcinomaPlatinum-Resistant Lung Small Cell CarcinomaPlatinum-Sensitive Lung Small Cell CarcinomaRecurrent Extensive Stage Lung Small Cell CarcinomaRecurrent Lung Small Cell Carcinoma

Interventions

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Computed Tomography

Undergo CT scan

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Tazemetostat Hydrobromide

Given PO

DRUG

Topotecan Hydrochloride

Given IV

Trial Locations (14)

10461

SUSPENDED

Montefiore Medical Center-Einstein Campus, The Bronx

10467

SUSPENDED

Montefiore Medical Center - Moses Campus, The Bronx

20007

RECRUITING

MedStar Georgetown University Hospital, Washington D.C.

20892

RECRUITING

NCI - Center for Cancer Research, Bethesda

21287

ACTIVE_NOT_RECRUITING

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27012

RECRUITING

Wake Forest University at Clemmons, Clemmons

27157

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

40536

SUSPENDED

University of Kentucky/Markey Cancer Center, Lexington

60611

ACTIVE_NOT_RECRUITING

Northwestern University, Chicago

75390

RECRUITING

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

90020

SUSPENDED

Keck Medicine of USC Koreatown, Los Angeles

90033

SUSPENDED

Los Angeles General Medical Center, Los Angeles

SUSPENDED

USC / Norris Comprehensive Cancer Center, Los Angeles

92663

SUSPENDED

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH